Please assess the completion status of the following clinical trial:

Trial Title: Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Good general health~* Available for the duration of the trial~* Willing to use acceptable forms of contraception for the duration of the study~Exclusion Criteria:~* Clinically significant neurologic, heart, lung, liver, rheumatologic, autoimmune, or kidney disease~* Behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may affect study participation~* Previously enrolled in an H7N3 influenza vaccine trial or in any study of an avian influenza vaccine~* Seropositive to the H7N3 influenza A virus (serum hemagglutination inhibition \[HI\] titer greater than 1:8)~* Illegal drug use or dependency determined by urine test~* Medical, work, or family problems as a result of alcohol or illicit drug use within 12 months prior to study entry~* History of severe allergic reaction~* Allergy to oseltamivir~* Asthma or reactive airways disease within 2 years prior to study entry~* History of Guillain-Barre syndrome~* HIV infected~* Hepatitis C virus infected~* Positive for hepatitis B surface antigen (HBsAg)~* Known immunodeficiency syndrome~* Use of corticosteroids or immunosuppressive drugs within 30 days prior to vaccination. Participants who have used topical corticosteroids are not excluded.~* Live vaccines within 4 weeks prior to study vaccination~* Killed vaccines within 2 weeks prior to study vaccination~* Absence of spleen~* Blood products within 6 months prior to study vaccination~* Current smoker unwilling to stop smoking for the duration of the study~* Have traveled to the Southern Hemisphere, Asia, or the United Kingdom within 14 days prior to study vaccination~* Have traveled on a cruise ship within 14 days prior to study vaccination~* Work in the poultry industry~* Other investigational vaccine or drug within 30 days prior to study vaccination~* Allergy to eggs or egg products~* Purified protein derivative (PPD) positive (positive tuberculosis \[TB\] test)~* Have family member with immunodeficiency~* Other condition that, in the opinion of the investigator, may interfere with the study~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 0.50 ml (0.25 ml in each nostril) of Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca) administered by nasal spray at two timepoints (at study entry and between Weeks 4 and 8)

Based on this trial design, predict the completion outcome and termination type (if applicable).